drugset / Trial / NCT06646211
High-dose Methotrexate Combined with Thiotepa and Zanubrutinib in the Treatment of Newly Diagnosed PCNSL (MTZ)
NaSingle-groupOpen-labelTreatment
Summary
This is a phase Ⅱ clinical study of Zanubrutinib(Z) in combination with methotrexate (M) and thiotepa(T) in treating newly diagnosed primary CNS lymphoma (PCNSL). The purpose of the study is to test the efficacy and tolerability of a combination treatment of MTZ regimen in treating patients who have newly diagnosed PCNSL
Timeline
- Start
- 2025-01-01
- Primary completion
- 2028-01-01
- Completion
- 2028-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Methotrexate | Small molecule | 3.5 g | Intravenous |
| Subject | Thiotepa | Other / unclassified | 40 mg/m2 | — |
| Subject | Zanubrutinib | Small molecule | 160 mg | — |